11th ESO-ESMO Masterclass in Clinical Oncology

30 ESCO credits

17.03.2012 - 22.03.2012

Ermatingen (Lake Constance), Switzerland

MASTERCLASS

Description

Chair: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: W. Gatzemeier, IT - R. Popescu, CH

AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, genito-urinary, gynaecological, head and neck and lung cancers.
Spotlight sessions will facilitate compact update on haematological diseases, therapeutic management of gliomas, cancer and pregnancy, side effects of systemic treatment, oral therapy, palliative care, cancer of unknown primary, sarcoma and treatment of melanoma.

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. The Clinical Sessions will be complemented by Tumour Board discussions. Furthermore, participants will deliver case presentations within small groups and discuss these with the chairmen and the faculty.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the side effects, oral therapy and palliative care sessions will be attended jointly.

THE MASTERCLASS IS:
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

The Masterclass in Clinical Oncology is an ESO-ESMO joint event

The masterclass is held in collaboration with the Flims Alumni Club

The Masterclass is part of the Masterclass-Online Study Program in Advanced Oncology of the University of Ulm

General information

ORGANISING SECRETARIAT
Francesca Marangoni
European School of Oncology
Via del Bollo, 4
20123 Milan, Italy
Ph: +39 02 85464525
Fax: +39 02 85464545
Email: fmarangoni@eso.net

CME ACCREDITATION
The Accreditation Council for Oncology in Europe (ACOE) has recommended that the event be granted 27 European CME credits.
The Masterclass has been furthermore accredited with 25 Category 1 ESMO MORA points.

ACKNOWLEDGEMENTS
ESO wishes to express its appreciation to Union Bank of Switzerland (UBS) and Wolfsberg Centre for their consideration and support to the 2012 Masterclass.

The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are:

- Platinum members: Amgen and Eisai
- Gold members: Eli Lilly, GlaxoSmithKline Oncology, Merck Serono, Roche
- Silver members: Celgene Corporation, Genomic Health, Novartis Oncology and Sanofi Oncology

Faculty list

FACULTY (as of January 2012)
M. Aapro, IMO Clinique de Genolier, FMH Oncologie-Hématologie, Genolier, CH
A. Albini, IRCCS MultiMedica, Science and Technology Sector, Milan, IT
F. André, Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, FR
J. Bernier, Genolier Swiss Medical Network, Department of Radiotherapy, Genolier, CH
T. Brodowicz, AKH Wien, Vienna, AT
P.G. Casali, Istituto Nazionale Tumori, Rep. di Medicina Oncologica, Milan, IT
G. Cavaletti, Università Milano-Bicocca, Dept. Neuroscience and Biomedical Technologies (DNTB), Monza, IT
G. Curigliano, European Institute of Oncology, Div. of Medical Oncology, Milan, IT
A. Dietz, University of Leipzig, Department of Otolaryngology, Leipzig, DE
S. Dirnhofer, Universität Basel, Pathology Institute, Basel, CH
T. Eisen, University of Cambridge, Dept. of Oncology, Cambridge, UK
C.C. Faivre-Finn, Hospital NHS Foundation Trust, Dept. of Clinical Oncology, Manchester, UK
J.M. Fitzpatrick, Mater Hospital and University College Dublin, Dept. of Urology and Surgery, Dublin, IE
K. Fizazi, Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, FR
W. Gatzemeier, Istituto Clinico Humanitas, Breast Unit, Rozzano, IT
M. Ghielmini, Oncology Institute of Southern Switzerland (IOSI), Div. of Medical Oncology, Bellinzona, CH
N. Harbeck, Klinikum Grosshadern, Breast Centre of Munich University, Munich, DE
A. Horwich, The Royal Marsden Hospital, Dept. of Radiotherapy, Sutton, UK
A. Hoy, Princess Alice Hospice, Dept. Of Palliative Medicine, Epson, Surrey, UK
R. Huddart, The Institute of Cancer Research (ICR) - Royal Marsden Hospital, Division of Radiotherapy and Imaging Sutton, Surrey, UK
C.H. Köhne, Klinikum Oldenburg, Klinik für Onkologie / Hämatologie, Oldenburg, DE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Dept. of Medical Oncology, Bellinzona, CH
P. Patel, University of Nottingham, Div. Clinical Oncology, Nottingham, UK
N. Pavlidis, University of Ioannina, Div. of Medical Oncology, Ioannina, GR
R. Popescu, Hirslanden Klinik Aarau, Tumor Center - Dept. of Medical Oncology, Aarau, CH
G.J. Poston, Aintree University Hospital, Dept. of Surgery, Liverpool, UK
G. Pruneri, European Institute of Oncology, Department of Pathology, and Milan University, Milan, IT
K. Redmond, Cancer World Editor, Lugano, CH
D. Schrijvers, Ziekenhuisnetwerk Antwerpen-Middelheim, Dept. of Haemato-Oncology, Antwerp, BE
D. Sebag-Montefiore, Institute of Oncology, St. James' University Hospital, Dept. of Medical Oncology, Leeds, UK
S. Segaert, University Hospital Sint-Rafaël, Dermatology Dept., Leuven, BE
C. Sessa, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
R.A. Stahel, University Hospital Zürich, Clinic and Policlinic for Oncology, Zurich, CH
E. Van Cutsem, University Hospital Gasthuisberg, Dept. Internal Medicine - Digestive Oncology Unit, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Department of Medical Oncology, Edegem, BE
R. von Moos, Cantonal Hospital Graubuenden, Dept. of Medical Oncology, Chur, CH
W. Weder, University Hospital Zurich, Div. of Thoracic Surgery, Zurich, CH
M. Weller, University Hospital Zurich, Department of Neurology, Zurich, CH

Programme

17 March

	Participants' arrival, airport transfers, registration
14:30	Clinical session Genito-urinary cancers I Chair: K. Fizazi, FR
	Prostate cancer: Local therapy: Surgery and radiotherapy A. Horwich, UK First-line endocrine treatment A. Horwich, UK Endocrine resistant - refractory K. Fizazi, FR
16:10	Clinical session Genito-urinary cancers II Chair: K. Fizazi, FR
	Bladder cancer: Neoadjuvant and adjuvant chemotherapy (locally advanced disease) R. Huddart, UK Metastatic disease: Systemic treatment R. Huddart, UK Renal cancer: Metastatic renal cancer: Evidence-based treatment T. Eisen, UK
17:50	Coffee break
18:20	Tumour board Genito-urinary cancers K. Fizazi, FR - A. Horwich, UK - T. Eisen, UK - R. Huddart, UK
20:30	*Dinner*

18 March

8:30	Clinical session Breast cancer I Chair: G. Viale, IT
	Pathology of breast cancer G. Pruneri, IT Early systemic treatment I: Neoadjuvant O. Pagani, CH Early systemic treatment I: Neoadjuvant, surgical viewpoint W. Gatzemeier, IT
10:00	Clinical session Breast cancer II Chair: O. Pagani, CH
	Early systemic treatment II: Adjuvant G. Curigliano, IT
10:45	*Coffee break*
	Treatment of metastatic breast cancer N. Harbeck, DE Radiotherapy: Key points J. Bernier, CH
12:15	Tumour board Breast cancer G. Viale, IT - J. Bernier, CH - G. Curigliano, IT - W. Gatzemeier, IT
13:15	Lunch
14:30	Supportive Care Session Early Antiemetics M. Aapro, CH G CSF and EPO M. Aapro, CH
15:00	Sponsored lecture Bone health in advanced cancer patients (SPCC lecture by Amgen) R. von Moos, CH
15:30	Spotlight session 1 Haematological diseases M. Ghielmini, CH
16:30	Coffee break
17:00	Sponsored lecture Management of senior ADULTS with prostate cancer - SIOG guidelines (SPCC lecture by Sanofi Oncology) J. Fitzpatrick, IE
17:30	Spotlight session 2 Therapeutic management of gliomas M. Weller, CH
18:00	Case presentations by participants (Genito-urinary cancers and breast cancer)
19:30	*Dinner*

19 March

8:30	Clinical session Gynaecological cancers Chair: J. Vermorken, BE
	Ovarian cancer J.B. Vermorken, BE Cervical and endometrial cancers C. Sessa, CH
10:30	*Coffee break*
11:00	Clinical session Head and neck cancer Chair: J. Bernier, CH
	Prognostic factors and surgical approach A. Dietz, DE Radiotherapy J. Bernier, CH Systemic therapy J.B. Vermorken, BE
13:00	*Lunch*
14:30	Tumour board Gynaecological cancers J.B. Vermorken, BE - C. Sessa, CH
15:00	Tumour board Head and neck cancer J.B. Vermorken, BE - A. Dietz, DE - C. Sessa, CH
15:30	Sponsored lecture How to evaluate genomic Classifiers in oncology (SPCC lecture by Genomic Health) S. Dirnhofer, CH
16:00	Sponsored lecture The importance of the mTOR pathway in Breast Cancer treatment (SPCC lecture by Novartis) F. André, FR
16:30	Spotlight session 3 Cancer and pregnancy N. Pavlidis, CH
17:00	*Coffee break*
17:30	Case presentations by participants (Gynaecological and head and neck cancers)
19:30	*Dinner*

20 March

8:30	Clinical session Gastro-intestinal tumours I Chair: E. Van Cutsem, BE
	Colon cancer: Adjuvant and neoadjuvant treatment of colorectal cancer K.H. Köhne, DE Systemic treatment in advanced disease E. Van Cutsem, BE
10:00	Sponsored lecture Metastasectomies in colorectal cancer (SPCC lecture by Merk) G.J. Poston, UK
10:30	*Coffee break*
11:00	Clinical session Gastro-intestinal tumours II Chair: E. Van Cutsem, BE
	Management of rectal cancer (surgery and radiotherapy) D. Sebag-Montefiore, UK Systemic treatment in early and advanced gastric cancer C.H. Köhne, DE
12:30	Tumour board Gastro-intestinal tumours E. Van Cutsem, BE - D. Sebag-Montefiore, UK - K.H. Köhne, DE
13:30	*Lunch*
14:30	Sponsored lecture Maintenance treatment in advanced non small cell lung cancer: a new treatment paradigm? (SPCC lecture by Lilly) T. Brodowicz, AT
15:00	e-ESO online session on New accomplishments in breast cancer chemoprevention A. Decensi, Galliera Hospital, Genoa, IT
16:00	Free time
19:30	*Dinner*

21 March

8:30	Clinical session Lung cancer and mesothelioma I Chair: R. Stahel, CH
	Surgery W. Weder, CH Radiotherapy C. Faivre-Finn, UK Non-small cell lung cancer systemic therapy R.A. Stahel, CH
10:30	*Coffee break*
11:00	Clinical session Lung cancer and mesothelioma II Chair: R.A. Stahel, CH
	Small cell lung cancer C. Faivre-Finn, UK Mesothelioma R.A. Stahel, CH
12:00	Tumour board Lung cancer R.A. Stahel, CH - W. Weder, CH - C. Faivre-Finn, UK
13:00	*Lunch*
14:15	Joint medics and nursing session Side effects of systemic treatment and their management
15:15	Cardiovascular toxicity A. Albini, IT Skin toxicity S. Segaert, BE Neurotoxicity G. Cavaletti, IT
15:30	Joint medics and nursing session Oral therapy: Adherence, compliance and drug interaction K. Redmond, CH
16:00	*Coffee break*
16:30	Joint medics and nursing session Palliative care
	Pain control D. Schrijvers, BE Advanced disease management A. Hoy, UK
18:00	Learning assessment tests
19:30	*Dinner*

22 March

8:30	Spotlight session 4 Cancer on unknown primary N. Pavlidis, GR
9:30	Spotlight session 5 Sarcoma P. Casali, IT
10:30	*Coffee break*
11:00	Spotlight session 6 Advances in systemic treatment of melanoma P. Patel, UK
12:00	*Closure*

« Back to "2012"